[go: up one dir, main page]

EA201800266A1 - ANTI-VIRUS PHARMACEUTICAL COMPOSITION - Google Patents

ANTI-VIRUS PHARMACEUTICAL COMPOSITION

Info

Publication number
EA201800266A1
EA201800266A1 EA201800266A EA201800266A EA201800266A1 EA 201800266 A1 EA201800266 A1 EA 201800266A1 EA 201800266 A EA201800266 A EA 201800266A EA 201800266 A EA201800266 A EA 201800266A EA 201800266 A1 EA201800266 A1 EA 201800266A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
antiviral pharmaceutical
glucan
antiviral
virus pharmaceutical
Prior art date
Application number
EA201800266A
Other languages
Russian (ru)
Other versions
EA036809B1 (en
Inventor
Юрий Захарович Толчеев
Вадим Алексеевич Козловский
Original Assignee
Юрий Захарович Толчеев
Вадим Алексеевич Козловский
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юрий Захарович Толчеев, Вадим Алексеевич Козловский filed Critical Юрий Захарович Толчеев
Publication of EA201800266A1 publication Critical patent/EA201800266A1/en
Publication of EA036809B1 publication Critical patent/EA036809B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к фармацевтической области, в частности к антивирусным фармацевтическим композициям. В изобретении раскрывается противовирусная фармацевтическая композиция, содержащая бета-глюкан, преимуществено в виде карбоксиметил бета-глюкана натриевой соли, и йотта-каррагенан в весовом соотношении от приблизительно 1 к 0,5 до приблизительно 1 к 5. Противовирусная фармацевтическая композиция может быть представлена в виде аэрозоля для доставки посредством дозирующего ингалятора в виде назального или вагинального спрея, в виде порошка для инсуффляций в полости тела или в виде геля.The present invention relates to the pharmaceutical field, in particular to antiviral pharmaceutical compositions. The invention discloses an antiviral pharmaceutical composition containing beta-glucan, advantageously in the form of carboxymethyl beta-glucan sodium salt, and yotta-carrageenan in a weight ratio of from about 1 to 0.5 to about 1 to 5. The antiviral pharmaceutical composition can be represented as an aerosol for delivery via a metered dose inhaler in the form of a nasal or vaginal spray, in the form of a powder for insufflations in the body cavity or in the form of a gel.

EA201800266A 2015-10-22 2016-10-24 Antiviral pharmaceutical composition EA036809B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
UAA201510327A UA118192C2 (en) 2015-10-22 2015-10-22 ANTI-VIRUS PHARMACEUTICAL COMPOSITION
PCT/UA2016/000122 WO2017069721A1 (en) 2015-10-22 2016-10-24 Antiviral pharmaceutical composition

Publications (2)

Publication Number Publication Date
EA201800266A1 true EA201800266A1 (en) 2018-09-28
EA036809B1 EA036809B1 (en) 2020-12-23

Family

ID=64604286

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201800266A EA036809B1 (en) 2015-10-22 2016-10-24 Antiviral pharmaceutical composition

Country Status (4)

Country Link
EA (1) EA036809B1 (en)
RU (1) RU2701514C2 (en)
UA (1) UA118192C2 (en)
WO (1) WO2017069721A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222581A1 (en) * 2017-05-29 2018-12-06 Resinnate Therapeutics Llc Methods and formulations for administering beta glucan
CN110582208A (en) * 2017-06-07 2019-12-17 雀巢产品有限公司 Powdered thickening agent which retains its tensile properties upon reconstitution and is useful for promoting safe swallowing in individuals with dysphagia
FI3773501T3 (en) * 2018-03-29 2023-12-19 The Materia Company Ltd Intravaginal formulation
SE546142C2 (en) * 2020-04-03 2024-06-11 Liw Innovation Ab New compositions for oral use
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1273576A (en) 1987-09-16 1990-09-04 Patrick A. Beauchamp Topical treatment for diseased skin disorders
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ITMI20032067A1 (en) 2003-10-23 2005-04-24 Unihart Corp SPRAY FORMULATION FOR THE TREATMENT OF VIRAL INFECTIONS.
US20060165623A1 (en) * 2005-01-24 2006-07-27 Terra Firma Natuals, Inc. Natural deodorant composition
WO2008067982A2 (en) * 2006-12-05 2008-06-12 Marinomed Biotechnologie Gmbh Use of carrageenan for treating rhinovirus infections
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
IT1393272B1 (en) 2009-02-20 2012-04-12 D M G Italia S R L PHARMACEUTICAL COMPOSITION CONTAINING MICROCOLLOIDAL SILVER AND CARBOSSIMETHYLBETHAGLAN FOR DISINFECTION OF NASAL MUCOSA AND ITS PREPARATION PROCEDURE

Also Published As

Publication number Publication date
WO2017069721A1 (en) 2017-04-27
UA118192C2 (en) 2018-12-10
RU2701514C2 (en) 2019-09-27
EA036809B1 (en) 2020-12-23
RU2017125688A (en) 2019-01-23
RU2017125688A3 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
EA201800266A1 (en) ANTI-VIRUS PHARMACEUTICAL COMPOSITION
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
PH12016500433B1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2018011100A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies.
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
MX2015015132A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
WO2016044839A3 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2013104892A8 (en) Application of high dose compounds via inhalation
WO2014007781A3 (en) Inhalation compositions
MX2015015150A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
MX2015009891A (en) Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy.
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
PH12014500249A1 (en) New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments
CL2015002702A1 (en) Micronized pharmaceutical compositions.
PH12022550432A1 (en) Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and use thereof
JOP20210075A1 (en) Derivatives of 4-pyrazine-2-yl-methylmorpholine and their use as a drug
LV15003A (en) A pharmaceutical composition for the control of weight gain
MX2017004633A (en) Formulations containing tiotropium, amino acid and acid and methods thereof.
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine